Print

Featured Studies Results

Comparing Shorter vs. Standard Radiation for High-Risk Prostate Cancer (High Five)

https://www.facingourrisk.org/research-clinical-trials/study/397 /comparing-shorter-vs-standard-radiation-for-high-risk-prostate-cancer

Clinicaltrials.gov identifier:
NCT05946213 (https://clinicaltrials.gov/show/NCT05946213)

Treatment
Phase 3 treatment study for high-risk prostate cancer to compare two different radiation therapy schedules

Testing COM701 Maintenance Treatment to Delay Cancer Growth After Platinum Chemotherapy for Ovarian Cancer That Has Come Back

https://www.facingourrisk.org/research-clinical-trials/study/381 /testing-com701-maintenance-treatment-to-delay-cancer-growth-after-platinum-chemotherapy-for-ovarian-cancer-that-has-come-back

Clinicaltrials.gov identifier:
NCT06888921 (https://clinicaltrials.gov/show/NCT06888921)

Treatment
Study for women with relapsed platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer who responded to their most recent platinum chemotherapy

ADHERE: Survey about Pancreatic Cancer Screening Options for People with Inherited Risk

https://www.facingourrisk.org/research-clinical-trials/study/368 /adhere-survey-about-pancreatic-cancer-screening-options-for-people-with-inherited-risk

Surveys, Registries, Interviews
Online survey about pancreatic cancer screening for people with an inherited mutation in genes that are linked to an increased risk of pancreatic cancer

Multi-Cancer Detection Blood Tests in Adults Without Cancer: Vanguard Study

https://www.facingourrisk.org/research-clinical-trials/study/394 /multi-cancer-detection-blood-tests-in-adults-without-cancer-vanguard-study

Clinicaltrials.gov identifier:
NCT06995898 (https://clinicaltrials.gov/show/NCT06995898)

Prevention
A study testing two multi-cancer detection blood tests in people who do not have cancer

Using the Drug Daraxonrasib in Surgically Removed Pancreatic Cancer (RASolute 304)

https://www.facingourrisk.org/research-clinical-trials/study/389 /using-the-drug-daraxonrasib-in-surgically-removed-pancreatic-cancer-rasolute-304

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 study for pancreatic cancer treatment after surgery and chemotherapy

Research Study on the Genetics of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer

Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)

Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356 /treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

Study of a New Oral Medication, Daraxonrasib After Surgery to Help Prevent Pancreatic Cancer from Returning

https://www.facingourrisk.org/research-clinical-trials/study/378 /study-of-a-new-oral-medication-daraxonrasib-after-surgery-to-help-prevent-pancreatic-cancer-from-returning

Clinicaltrials.gov identifier:
NCT07252232 (https://clinicaltrials.gov/show/NCT07252232)

Treatment
Phase 3 treatment trial for pancreatic cancer that was removed by surgery

Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery

https://www.facingourrisk.org/research-clinical-trials/study/386 /comparing-two-vaccine-treatments-with-immunotherapy-for-pancreatic-cancer-before-and-after-surgery

Clinicaltrials.gov identifier:
NCT06782932 (https://clinicaltrials.gov/show/NCT06782932)

Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment

Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/328 /treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib

Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)

Treatment
Treatment study for people with advanced or metastatic cancers

Treating Advanced Endometrial Cancer with Targeted Therapies (ComboMATCH)

https://www.facingourrisk.org/research-clinical-trials/study/375 /treating-advanced-endometrial-or-ovarian-cancer-with-targeted-therapies-combomatch

Clinicaltrials.gov identifier:
NCT05554328 (https://clinicaltrials.gov/show/NCT05554328)

Treatment
Phase 2 treatment study for recurrent endometrial cancer

Health and Medicine Decision-Making Study

https://www.facingourrisk.org/research-clinical-trials/study/382 /health-and-medicine-decision-making-study

Surveys, Registries, Interviews
Study for people diagnosed with a complex health condition such as cancer, diabetes or an autoimmune disorder

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314 /neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Vaccine for People at High Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/365 /vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT05013216 (https://clinicaltrials.gov/show/NCT05013216)

Prevention
Phase 1 pancreatic cancer prevention study for people at high risk

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

https://www.facingourrisk.org/research-clinical-trials/study/371 /comparing-an-investigational-targeted-drug-azd5335-to-standard-treatments-in-people-with-platinumresistant-ovarian-cancer-trevioc01

Clinicaltrials.gov identifier:
NCT07218809 (https://clinicaltrials.gov/show/NCT07218809)

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

https://www.facingourrisk.org/research-clinical-trials/study/372 /using-a-blood-test-to-detect-early-cancer-recurrence-after-treatment-oracle

Clinicaltrials.gov identifier:
NCT05059444 (https://clinicaltrials.gov/show/NCT05059444)

Treatment
Post-treatment study to monitor for recurrence

Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T

https://www.facingourrisk.org/research-clinical-trials/study/364 /treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t

Clinicaltrials.gov identifier:
NCT06878248 (https://clinicaltrials.gov/show/NCT06878248)

Treatment
Phase 1 treatment study for people with advanced solid tumors

An Early Detection and Prevention Study for People with an Increased Risk of Cancer (InAdvance)

https://www.facingourrisk.org/research-clinical-trials/study/385 /an-early-detection-and-prevention-study-for-people-with-an-increased-risk-of-cancer-inadvance

Clinicaltrials.gov identifier:
NCT05463796 (https://clinicaltrials.gov/show/NCT05463796)

Prevention
Study for people at risk of cancer, including previvors, survivors and family members

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.